BioLineRx presents data on BL-1021, a New Chemical Entity for treatment of neuropathic pain, at 13th World Congress on Pain, Montreal, Canada

August 30, 2010
Jerusalem, Israel, August 30, 2010. BioLineRx is pleased to announce that data on BL-1021, a new chemical entity (NCE) for treatment of neuropathic pain, will be presented at 13th World Congress on Pain, Montreal Canada. This Congress is the biennial meeting of the International Association for the Study of Pain (IASP), the world's leading professional forum for science, practice and education in the field of pain, with over 6500 members worldwide.

In vivo experiments conducted with BL-1021 have demonstrated the efficacy of a single administration of BL-1021 in the Chung model of neuropathic pain. BL-1021 was found to be safe and well tolerated at effective doses with a wide safety window without significant toxicity. In this Congress, the results of repeated administration of BL-1021 for 14 days in the Chung and CCI models of Neuropathic Pain will be presented showing the compound's efficacy.

These results show that BL-1021 is an effective and promising NCE for the treatment of neuropathic pain and may represent a safe and potent alternative to present treatments administered for neuropathic pain.
(Please click on World Congress on Pain logo on "Overview" page to see abstract)
Potential life-changing treatments are on the way

Each molecule in our development pipeline is carefully selected for its potential ability to improve upon the standard of care, delivering maximum value to patients